Multidrug-resistant tuberculosis;Tuberculosis multirresistente

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue SUPPL. 13, 2008, Pages 54-60

  Alcaide, Fernando ^a,b   Santín, Miguel ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Multiresistance; Sensitivity tests; Treatment; Tuberculosis

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; AMOXICILLIN PLUS CLAVULANIC ACID; CAPREOMYCIN; CLARITHROMYCIN; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL STRAIN; COMORBIDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIGRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PUBLIC HEALTH; SPAIN; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION; CLASSIFICATION; DISEASE TRANSMISSION; DRUG EFFECT; EVIDENCE BASED MEDICINE; HEALTH; ISOLATION AND PURIFICATION; METHODOLOGY; MICROBIOLOGICAL EXAMINATION; PRACTICE GUIDELINE; REVIEW;

ANTITUBERCULAR AGENTS; EVIDENCE-BASED MEDICINE; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINES AS TOPIC; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 60249090044     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1157/13128781     Document Type: Article

References (44)

1. World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO report 2008. WHO Press, 2008. WHO/HTM/TB/2008. 393.
2. The WHO/IUATLD Global project on anti-tuberculosis drug resistance surveillance. Anti-tuberculosis drug resistance in the World 2002-2007. Fourth Global Report. World Health Organization, WHO Press, 2008. WHO/HTM/TB/2008.394.
3. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO Press, 2006. WHO/HTM/TB/2006.361.
4. Wright A., Bai G., Barrera L., Boulahbal F., Martín-Casabona N., Gilpin C., et al. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR 55 (2006) 301-305
5. Frieden T.R., Sterling T., Pablos-Méndez A., Kilburn J.O., Cauthen G.M., and Dooley S.W. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 328 (1993) 521-526
6. EuroTB (InVS/KNCV) and the national coordinators for tuberculosis surveillance in the WHO European Region. Surveillance of tuberculosis in Europe. Report on tuberculosis cases notified in 2005. Sain-Maurice, France: Institut de Veille Sanitaire; 2007.
7. Guerrero A., Cobo J., Fortun J., Navas E., Quereda C., Asensio A., et al. Nosocomial transmisión of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection. Lancet 350 (1997) 1738-1742
8. Samper S., Iglesias M.J., Rabanaque M.J., Gómez L.I., Lafoz M.C., Jiménez M.S., et al. Spanish Working Group on MDR-TB. Systematic molecular characterization of multidrug-resistant Mycobacterium tuberculosis complex isolates from Spain. J Clin Microbiol 43 (2005) 1220-1227
9. Middlebrook G., and Cohn M.L. Some observation on the pathogenicity of isoniazid-resistant variants tubercle bacilli. Science 118 (1953) 297-299
10. Zhang Y., and Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. In: Hatfull G.F., and Jacobs Jr. W.R. (Eds). Molecular genetics of mycobacteria (2000), American Society for Microbiology, Washington DC 235-254
11. a ed. (2005), SEIMC, Madrid
12. Woods G.L., Warren N.G., and Inderlied C.B. Susceptibility test methods: mycobacteria, Nocardia, and other actinomycetes. In: Murray P.R., Baron E.J., Jorgensen J.H., Landry M.L., and Pfaller M.A. (Eds). Manual of clinical microbiology. 9th ed. (2007), American Society for Microbiology, Washington DC 1223-1247
13. National Committee for Clinical Laboratory Standards. Susceptibility testing for mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard. NCCLS document M24-A (2003), National Committee for Clinical Laboratory Standards, Wayne, Pe
14. Laszlo A., Rahman M., Espinal M., Raviglione M., and WHO/IUATLD Network of Supranational Reference Laboratories. Quality Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Int J Tuberc Lung Dis 6 (2002) 748-756
15. World Health Organization. Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOTS-plus (2001), WHO Press WHO/CDS/TB/2001.288
16. Galí N., Domínguez J., Blanco S., Prat C., Alcaide F., Coll P., et al. Use of a mycobacteriophage-based assay for rapid assessment of susceptibilitie s of Mycobacterium tuberculosis isolates to isoniazid and influence of resistance level on assay performance. J Clin Microbiol 44 (2006) 201-205
17. Forbes B.A., Pfyffer G., and Eisenach K.D. Molecular diagnosis of mycobacterial infections. In: Cole S.T., Eisenach K.D., McMurray D.N., and Jacobs Jr. W.R. (Eds). Tuberculosis and the Tubercle Bacillus (2005), American Society for Microbiology, Washington DC 89-98
18. García de Viedma D., Lasala F., Chaves F., Alcalá L., and Bouza E. New real-time PCR able to detect in a single tube multiple rifampin resistance mutations and high-level isoniazid resistance mutations in Mycobacterium tuberculosis. J Clin Microbiol 40 (2002) 988-995
19. Espasa M., González-Martín J., Alcaide F., Aragón L.M., Lonca J., Manterola J.M., et al. Direct detection in clinical samples of multiple gene mutations causing resistance of Mycobacterium tuberculosis to isoniazid and rifampicin using fluorogenic probes. J Antimicrob Chemother 55 (2005) 860-865
20. Aragón L.M., Navarro F., Heiser V., Garrido M., Español M., and Coll P. Rapid detection of specific gene mutations associated with isoniazid and rifampicin resistance in Mycobacterium tuberculosis clinical isolates using non-fluorescent low-density DNA microarrays. J Antimicrob Chemother 57 (2006) 825-831
21. Mäkinen J., Marttila H.J., Marjamäki M., Viljanen M.K., and Soini H. Comparison of two commercially available DNA line assays for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 44 (2006) 350-352
22. American Thoracic Society. Levels of Laboratory services of micobacterial disease: official statement of the American Thoracic Society. Am Rev Respir Dis 128 (1983) 213
23. Klietmann W. Resistance and susceptibility testing for Mycobacterium tuberculosis. Clin Microbiol Newsl 17 (1995) 65-69
24. American Thoracic Society Documents. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 167 (2003) 603-662
25. Martín-Casabona N., Alcaide F., Coll P., González J., Manterola J.M., Salvadó M., et al. Farmacorresistencia de Mycobacterium tuberculosis. Estudio multicéntrico en el área de Barcelona. Med Clin (Barc) 115 (2000) 493-498
26. Mukherjee J.S., Rich M.L., Socci A.R., Joseph J.K., Virú F.A., Shin S.S., et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363 (2004) 474-481
27. Burgos M., González L.C., Paz E.A., Gournis E., Kawamura L.M., Schecter G., et al. Treatment of multidrug resistant tuberculosis in San Francisco: an outpatient-based approach. Clin Infect Dis 40 (2005) 968-975
28. Fischl M.A., Daikos G.L., Uttamchandani R.B., Poblete R.B., Moreno J.N., Reyes R.R., et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multidrug-resistant bacilli. Ann Intern Med 117 (1992) 184-190
29. Rullan J.V., Herrera D., Cano R., Moreno V., Godoy P., Peiro E.F., et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain. Emerg Infect Dis 2 (1996) 125-129
30. Sepkowitz K.A., Raffalli J., Riley L., Kiehn T.E., and Armstrong D. Tuberculosis in the AIDS era. Clin Microbiol Rev 8 (1995) 180-199
31. Goble M., Iseman M.D., Madsen L.A., Waite D., Ackerson L., and Horsburgh Jr. C.R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 328 (1993) 527-532
32. Caminero J.A. Treatment of multidrug-resistant tuberculosis: evidence and controversies. Int J Tuberc Lung Dis 10 (2006) 829-837
33. Espinal M.A., Laserson K., Camacho M., Fusheg Z., Kim S.J., Tlali R.E., et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 5 (2001) 887-893
34. Huebner R.E., Good R.C., and Tokars J.I. Current practices in mycobacteriology: results of a survey of state public health laboratories. J Clin Microbiol 31 (1993) 771-775
35. Pablos-Méndez A. Working alliance for TB drug development, Cape Town, South Africa, February 8th, 2000. Declaration. Int J Tuberc Lung Dis 4 (2000) 489-490
36. Ginsberg A.M., and Spigelman M. Challenges in tuberculosis drug research and development. Nat Med 13 (2007) 290-294
37. Fortún J., Martín-Dávila P., Navas E., Pérez-Elías M.J., Cobo J., Tato M., et al. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 56 (2005) 180-185
38. Weis S.E., Slocum P.C., Blais F.X., King B., Nunn M., and Matney G.B. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 330 (1994) 1179-1184
39. Jensen P.A., Lambert L.A., Iademarco M.F., and Ridzon R. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care setting, 2005. MMWR Recomm Rep 54 (2005) 1-141
40. Fraser A., Paul M., Attamna A., and Leibovici L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis 10 (2006) 19-23
41. Papastavros T., Dolovich L.R., Holbrook A., Whitehead L., and Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of the latent multidrug-resistant tuberculosis. CMAJ 167 (2002) 131-136
42. Munsiff S.S., Li J., Cook S.V., Piatek A., Laraque F., Ebrahimhadeh A., et al. Trends in drug-resistant Mycobacterium tuberculosis in New York City, 1991-2003. Clin Infect Dis 42 (2008) 1702-1710
43. Blower S., and Supervie V. Predicting the future of XDR tuberculosis. Lancet Infect Dis 7 (2007) 443
44. Espinal M.A. The global situation of MDR-TB. Tuberculosis 83 (2003) 44-51